ITEM 7.01REGULATION FD DISCLOSURE

On January 22, 2020, Vitro Diagnostics Inc. ("Vitro Biopharma") issued a press release announcing a private placement of Units consisting of Series A Convertible Preferred Stock ("Series A Preferred"), Class A Warrants and Class B Warrants (the "Offering"). The Company has authorized the Offering of up to $1,000,000 in Units. Terms of the Offering are set forth in the Press Release filed herewith as Exhibit 99.1.

On January 23, 2030, the CEO of the Company issued a Letter to Shareholders announcing results of operations and financial condition for the fiscal year ended October 31, 2019. A copy of the Letter to Shareholders is filed herewith as Exhibit 99.2.

The information in this Current Report on Form 8-K furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section, and they shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. By filing this Current Report on Form 8-K and furnishing this information pursuant to Item 7.01, The Company makes no admission as to the materiality of any information in this Current Report on Form 8-K, including Exhibit 99.1, that is required to be disclosed solely by Regulation FD.







ITEM 9.01:EXHIBITS



  Item Title

  99.1   Press Release
  99.2   Letter to Shareholders

© Edgar Online, source Glimpses